SEC Form 4 · accession 0001437749-18-004973
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stefan C Linn
Officer — Chief Operating Officer
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 15, 2018 | A | 5,634 | $0.00 | A | 38,165 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F2 | $13.24 | Mar 15, 2018 | A | 24,637 | A | — | Mar 15, 2028 | Ordinary Shares | 24,637 | 24,637 | D |
Explanation of responses
- F1Options granted under Issuer's 2013 Share Incentive Plan.
- F2Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2019 through January 1, 2022.